These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37328868)

  • 1. Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden.
    Kågström E; Lannergård A; El Khosht J; Lörelius P; Månflod J; Strömdahl S
    Harm Reduct J; 2023 Jun; 20(1):77. PubMed ID: 37328868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden.
    Lindqvist K; Thorin Z; Kåberg M
    Harm Reduct J; 2023 Jun; 20(1):72. PubMed ID: 37308951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era.
    Gahrton C; Navér G; Warnqvist A; Dalgard O; Aleman S; Kåberg M
    Int J Drug Policy; 2024 Jun; 128():104433. PubMed ID: 38703622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
    van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M
    Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
    Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
    BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Addiction; 2018 Mar; 113(3):545-563. PubMed ID: 28891267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review.
    Abdul-Quader AS; Feelemyer J; Modi S; Stein ES; Briceno A; Semaan S; Horvath T; Kennedy GE; Des Jarlais DC
    AIDS Behav; 2013 Nov; 17(9):2878-92. PubMed ID: 23975473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
    Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
    Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya.
    Stone J; Fraser H; Walker JG; Mafirakureva N; Mundia B; Cleland C; Bartilol K; Musyoki H; Waruiru W; Ragi A; Bhattacharjee P; Chhun N; Lizcano J; Akiyama MJ; Cherutich P; Wisse E; Kurth A; Luhmann N; Vickerman P
    AIDS; 2022 Dec; 36(15):2191-2201. PubMed ID: 36111533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review.
    Des Jarlais DC; Feelemyer JP; Modi SN; Abdul-Quader A; Hagan H
    BMC Public Health; 2013 Jan; 13():53. PubMed ID: 23332005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
    E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
    Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran.
    Khezri M; Mirzazadeh A; Shokoohi M; Sharafi H; Ghalekhani N; Tavakoli F; Mehmandoost S; Mousavian G; Imani M; Kakavand-Ghalehnoei R; Komasi A; Gouya MM; Haghdoost AA; McFarland W; Karamouzian M; Sharifi H
    Drug Alcohol Depend; 2023 Feb; 243():109751. PubMed ID: 36621200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination.
    Kåberg M; Navér G; Hammarberg A; Weiland O
    J Viral Hepat; 2018 Dec; 25(12):1452-1461. PubMed ID: 29998522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
    Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
    J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews.
    Fernandes RM; Cary M; Duarte G; Jesus G; Alarcão J; Torre C; Costa S; Costa J; Carneiro AV
    BMC Public Health; 2017 Apr; 17(1):309. PubMed ID: 28399843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.